Clinics I work with
My reviews
Selected research
-
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.
Future oncology (London, England)
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Nature
-
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clinical trials
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
As the primary endpoint for the treatment comparison, it is the duration of time from randomization to the time of disease progression (in the CNS or systemically) or death. In addition, as a secondary endpoint, PFS is measured fr...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 885-3882
4.8